Literature DB >> 20874716

Myofibroblasts protect myoblasts from intrinsic apoptosis associated with differentiation via β1 integrin-PI3K/Akt pathway.

Yu Zhang1, Hai Li, Zhengxing Lian, Ning Li.   

Abstract

Skeletal myoblasts withdrawing from cell cycle is a prerequisite for myodifferentiation, while upon proliferation/differentiation transformation, a large portion of myoblasts will undergo apoptosis. Skeletal fibroblasts, residing in muscle tissue both during and post myogenesis, have been proofed to play pivotal roles in muscle development, while their effect on myoblast apoptosis being coincident with differentiation has not been reported. Using a membrane insert co-culture system, we studied it and found that the mitochondrial pathway played a crucial role in myoblast apoptosis during differentiation, and fibroblasts promoted not only cell cycle withdrawal but also myoblast survival in a paracrine fashion, which was coupled with upregulations of β1 integrin, phosphorylated Akt and anti-apoptotic protein Bcl2. To determine the effect of β1 integrin in the process, we transfected myoblasts with siRNA specific for β1 integrin before co-culture and found that β1 integrin knockdown abolished anti-apoptotic ability of myoblasts and inhibited Akt activation and Bcl2 expression. Blockage of PI3K/Akt pathway with wortmannin also seriously impaired the protective effect of fibroblasts on myoblasts and fibroblast-induced Bcl2 expression. The data demonstrated that fibroblasts protected myoblasts from intrinsic apoptosis associated with differentiation, and β1 integrin-PI3K/Akt pathway activation was required for the process.
© 2010 The Authors. Journal compilation © 2010 Japanese Society of Developmental Biologists.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20874716     DOI: 10.1111/j.1440-169X.2010.01209.x

Source DB:  PubMed          Journal:  Dev Growth Differ        ISSN: 0012-1592            Impact factor:   2.053


  6 in total

1.  Regulation of the muscle fiber microenvironment by activated satellite cells during hypertrophy.

Authors:  Christopher S Fry; Jonah D Lee; Janna R Jackson; Tyler J Kirby; Shawn A Stasko; Honglu Liu; Esther E Dupont-Versteegden; John J McCarthy; Charlotte A Peterson
Journal:  FASEB J       Date:  2013-12-27       Impact factor: 5.191

2.  Genome-Wide Identification and Characterization of Long Non-Coding RNAs in Embryo Muscle of Chicken.

Authors:  Lingbin Liu; Lingtong Ren; Anfang Liu; Jinxin Wang; Jianhua Wang; Qigui Wang
Journal:  Animals (Basel)       Date:  2022-05-16       Impact factor: 3.231

3.  Phenotype selection reveals coevolution of muscle glycogen and protein and PTEN as a gate keeper for the accretion of muscle mass in adult female mice.

Authors:  Mandy Sawitzky; Anja Zeissler; Martina Langhammer; Maximilian Bielohuby; Peggy Stock; Harald M Hammon; Solvig Görs; Cornelia C Metges; Barbara J M Stoehr; Martin Bidlingmaier; Carolin Fromm-Dornieden; Bernhard G Baumgartner; Bruno Christ; Bertram Brenig; Gerhard Binder; Friedrich Metzger; Ulla Renne; Andreas Hoeflich
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

Review 4.  The Evolution of Complex Muscle Cell In Vitro Models to Study Pathomechanisms and Drug Development of Neuromuscular Disease.

Authors:  Jana Zschüntzsch; Stefanie Meyer; Mina Shahriyari; Karsten Kummer; Matthias Schmidt; Susann Kummer; Malte Tiburcy
Journal:  Cells       Date:  2022-04-05       Impact factor: 6.600

5.  CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia.

Authors:  Tianzhuo Zhang; Danna Wei; Tingting Lu; Dan Ma; Kunlin Yu; Qin Fang; Zhaoyuan Zhang; Weili Wang; Jishi Wang
Journal:  RSC Adv       Date:  2020-01-03       Impact factor: 4.036

6.  Fibroblasts influence muscle progenitor differentiation and alignment in contact independent and dependent manners in organized co-culture devices.

Authors:  Nikhil Rao; Samantha Evans; Danique Stewart; Katrina H Spencer; Farah Sheikh; Elliot E Hui; Karen L Christman
Journal:  Biomed Microdevices       Date:  2013-02       Impact factor: 2.838

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.